Last reviewed · How we verify

NCT04194398

OCS Lung Expand Post-Approval Study - Expand Follow-Up Data Collection

Completed Last updated 7 April 2022
What this trial tests

trial testing OCS Lung System in OCS Lung System in 79 participants. Completed in 30 September 2021.

Timeline
31 December 2018
Primary endpoint
30 September 2021
30 September 2021

Quick facts

Lead sponsorTransMedics
StatusCompleted
Study typeOBSERVATIONAL
Enrollment79
Start date31 December 2018
Primary completion30 September 2021
Estimated completion30 September 2021
Sites8 locations across Belgium, United States, Germany

Drugs / interventions tested

Conditions studied

Sponsor

TransMedics — full company profile →

Who can join

18 and older, any sex, with OCS Lung System. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Collection of five year follow-up data on patients who have already participated in the EXPAND Lung trial and have had transplants with donor lungs preserved on the OCS Lung System.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Long-term outcomes of the international EXPAND trial of Organ Care System (OCS) Lung preservation for lung transplantation.
    Loor G, Warnecke G, Villavicencio MA, Smith MA, et al · · 2025 · cited 5× · PMID 40686680 · DOI 10.1016/j.eclinm.2025.103334

Verify or expand the search:

Other trials of OCS Lung System

Trials testing the same drug.

Other TransMedics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04194398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing